Dr. Daniel T. Layish, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Boston University School of Medicine (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,485
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: Boston University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
FL license ME72566 -
Critical Care Medicine (Internal Medicine) Physician
FL license ME72566 -
Internal Medicine Physician
FL license ME72566 -
Sleep Medicine (Internal Medicine) Physician
FL license ME72566
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Orlando Orlando, FL
- Orlando Health Orlando, FL
- Adventhealth Waterman Tavares, FL
Medical groups
- Florida Hospital Medical Group Inc (1,755 clinicians)
- Central Florida Pulmonary Group PA (15 clinicians)
- Solution Health Specialists LLC (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,485
- Services billed
- 5,108
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 1,468 | 477 |
| Established patient office or other outpatient visit, 30-39 minutes | 624 | 459 |
| Established patient office or other outpatient visit, 20-29 minutes | 604 | 445 |
| Test to measure expiratory airflow and volume | 493 | 448 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 398 | 344 |
| X-ray of chest, 2 views | 391 | 344 |
| Test to examine how well the lungs exchange gases | 338 | 327 |
| Test to determine lung volumes using sensors | 334 | 324 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 312 | 186 |
| New patient office or other outpatient visit, 45-59 minutes | 109 | 109 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Orlando, FL | 480 |
| Trikafta (elexacaftor/tezacaftor/ivacaft) | 475 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Orlando, FL | 381 |
| Montelukast Sodium Other prescribers in Orlando, FL | 351 |
| Azithromycin Other prescribers in Orlando, FL | 311 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Orlando, FL | 129 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Orlando, FL | 128 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Orlando, FL | 111 |
| Prednisone Other prescribers in Orlando, FL | 108 |
| Zenpep (lipase/protease/amylase) Other prescribers in Orlando, FL | 104 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 82 payments worth $5,526 in total to this clinician.
| Lilly USA, LLC | $3,468 |
|---|---|
| Insmed, Inc. | $275 |
| Actelion Pharmaceuticals US, Inc. | $269 |
| GlaxoSmithKline, LLC. | $244 |
| Avadel Cns Pharmaceuticals, LLC | $222 |
| Viatris Specialty LLC | $171 |
| Harmony Biosciences LLC | $145 |
| United Therapeutics Corporation | $135 |
| Compensation for services other than consulting (speaking, faculty) | $3,450 |
|---|---|
| Food and Beverage | $1,594 |
| Education | $282 |
| Consulting Fee | $200 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Apr 29, 2025 | Compensation for services other than consulting (speaking, faculty) ZEPBOUND · Obesity | $3,450 |
| Avadel Cns Pharmaceuticals, LLC Apr 15, 2025 | Consulting Fee LUMRYZ · CENTRAL NERVOUS SYSTEM CNS NEUROLOGY · in-kind | $200 |
| Actelion Pharmaceuticals US, Inc. May 1, 2025 | Education OPSUMIT; UPTRAVI · Cardiology · in-kind | $99.95 |
| Actelion Pharmaceuticals US, Inc. Jul 30, 2025 | Education OPSUMIT; UPTRAVI · Cardiology · in-kind | $78.99 |
| Merck Sharp & Dohme LLC Sep 30, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Sep 30, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Sep 30, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Sep 30, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $33,419 in research payments for these studies, mostly to the institutions running them.
- A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
United Therapeutics Corporation · Completed · NCT03626688 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
United Therapeutics Corporation · Enrolling by invitation · NCT03683186 - Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04751487 - A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIR…
Boehringer Ingelheim International GmbH - A Phase 2, Open-label Study Evaluating Efficacy and Safety of VX-864 in Subjects With Alpha-1 Antitrypsin Deficiency Who Have the PiZZ Genotype, Over 48 Weeks
Vertex Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.